Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Plus Therapeutics (PSTV) Non-Current Assets (2016 - 2025)

Plus Therapeutics (PSTV) has disclosed Non-Current Assets for 16 consecutive years, with $1.2 million as the latest value for Q4 2025.

  • Quarterly Non-Current Assets fell 15.94% to $1.2 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $4.6 million through Dec 2025, down 26.73% year-over-year, with the annual reading at $1.2 million for FY2025, 15.94% down from the prior year.
  • Non-Current Assets for Q4 2025 was $1.2 million at Plus Therapeutics, up from $1.1 million in the prior quarter.
  • The five-year high for Non-Current Assets was $2.9 million in Q1 2021, with the low at $1.1 million in Q3 2025.
  • Average Non-Current Assets over 5 years is $1.9 million, with a median of $1.8 million recorded in 2024.
  • The sharpest move saw Non-Current Assets decreased 0.05% in 2024, then plummeted 37.99% in 2025.
  • Over 5 years, Non-Current Assets stood at $2.7 million in 2021, then fell by 22.73% to $2.0 million in 2022, then fell by 24.2% to $1.6 million in 2023, then fell by 11.58% to $1.4 million in 2024, then fell by 15.94% to $1.2 million in 2025.
  • According to Business Quant data, Non-Current Assets over the past three periods came in at $1.2 million, $1.1 million, and $1.1 million for Q4 2025, Q3 2025, and Q2 2025 respectively.